¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 232¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.
ÀÌ ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 8.25%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚ¿Í ÀÇ·á Àü¹®°¡µéÀº Ç÷´ç ¸ð´ÏÅ͸µ ±â±â¿¡¼ Å« ÀÌÀÍÀ» ¾ò°í ÀÖ½À´Ï´Ù. Ç÷´ç ¸ð´ÏÅ͸µ ±â±â´Â ÁýÁßÀûÀÎ ´ç´¢º´ Ä¡·áÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ³Î¸® ¹Þ¾Æ µé¿©Áö°í ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ´ç´¢º´ ȯÀÚ´Â ¾îµð¿¡ ÀÖµç °£ÆíÇÏ°í Æí¸®ÇÏ°Ô ¸î ºÐ À̳»¿¡ Ç÷´çÄ¡¸¦ ÃøÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â´Â Ç÷´ç ¼öÄ¡¸¦ Áö¼ÓÀûÀÌ°í ½Ç½Ã°£À¸·Î ºÐ¼®ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ È¯ÀÚ°¡ ½Ä»ç ¼·Ãë·®°ú Àν¶¸° º¹¿ë·®À» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. °Ô´Ù°¡ Á¤Å© Ǫµå, ¾ËÄÚ¿Ã, Èí¿¬ ¼·Ã븦 Æ÷ÇÔÇÑ ¾É±â ½¬¿î ¶óÀÌÇÁ ½ºÅ¸ÀÏÀ̳ª º¸´Ù ¾ÈÀüÇÏ°í ½Å¼ÓÇÑ Áø´Ü¿¡ ´ëÇÑ ¿ä±¸ÀÇ ±ÞÁõ°ú °°Àº ¿äÀÎÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ¹Ð¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±¹Á¦ ´ç´¢º´¿¬ÇÕ(IDF)¿¡ µû¸£¸é ´ç´¢º´ ȯÀÚÀÇ ÃѼö´Â 2030³â±îÁö 6¾ï 4,300¸¸ ¸í(11.3%), 2045³â±îÁö 7¾ï 8,300¸¸ ¸í(12.2%)À¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºñ¸¸Àº ´ç´¢º´ À¯º´·üÀ» ³ôÀÌ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ºñ¸¸ÀÎÀÌ ´ç´¢º´À» ÀÏÀ¸Å³ °¡´É¼ºÀº ºñ¸¸ÀÌ ¾Æ´Ñ »ç¶÷ÀÇ ÃÖ´ë 80¹èÀÔ´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é 18¼¼ ÀÌ»óÀÇ 6¾ï 5,000¸¸ ¸íÀÌ ºñ¸¸ÀÔ´Ï´Ù. °Ô´Ù°¡ ´ç´¢º´ ÅëÁ¦¸¦ À§ÇÑ Á¤ºÎ¿Í ±¹Á¦ ´ç´¢º´ ¿¬ÇÕ(IDF)°ú °°Àº °Ç° °ü¸® Á¶Á÷ÀÇ Áö¼ÓÀûÀÎ ³ë·ÂÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀÌ ºü¸¥ ¼Óµµ·Î »ó½ÂÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ÀÌÇØ°ü°èÀÚ¿Í Çù·ÂÀÚ ³×Æ®¿öÅ©¸¦ ÅëÇØ ÀÌ·¯ÇÑ Á¶Á÷Àº ÇÊ¿äÇÑ Àü¹® Áö½ÄÀ» Á¦°øÇÏ°í ´ç´¢º´ °è¹ß Ä·ÆäÀÎÀ» Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ ÀÇ·áºñ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- À¯¸®ÇÑ »óȯ Á¤Ã¥, ÁÖ¿ä ±â¾÷ÀÇ ÇöÁö ÁøÃâ, Á¤ºÎÀÇ Áö¿øÃ¥¿¡ ÀÇÇØ ºÏ¹Ì°¡ 2023³â¿¡ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- Á¦Ç°º°·Î´Â ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â°¡ 2023³â 66.37%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
- CÇ÷´ç ¸ð´ÏÅ͸µ ±â±âÀÇ Á¦Ç° ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÎ¹®ÀÌ µÉ Àü¸ÁÀÔ´Ï´Ù.
- ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â¿¡¼´Â °Ë»ç ½ºÆ®¸³ÀÇ »ç¿ë·üÀÌ ³ô°í °¡°Ýµµ Àú·ÅÇϱ⠶§¹®¿¡ 2023³â¿¡´Â °Ë»ç ½ºÆ®¸³ ºÎ¹®ÀÌ ÃÖ´ëÀÇ ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â ÀçÅà ÄÉ¾î ºÐ¾ß°¡ ¿¹Ãø ±â°£ Áß¿¡ ±Þ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§
Á¦2Àå Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ÁÖ¿ä ¿ä¾à
- ½ÃÀå ÇöȲ
- Á¦Ç° ¹× ÃÖÁ¾ ¿ëµµÀÇ ½º³À¼¦
- °æÀï ±¸µµÀÇ ½º³À¼¦
Á¦3Àå Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : º¯¼ö, µ¿Çâ ¹× ¹üÀ§
- ½ÃÀå ¼¼ºÐÈ ¹× ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ¼¼°è ³ëÀÎ Àα¸ Áõ°¡
- ´ç´¢º´ ȯÀÚ Áõ°¡
- ´ç´¢º´ ¿¹¹æ Äɾ ´ëÇÑ ÀǽÄÀÇ Çâ»ó
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼®-Porter's Five Forces ºÐ¼®
- PESTLE ºÐ¼®
- °¡°Ý ºÐ¼®
Á¦4Àå Ç÷´ç ¸ð´ÏÅ͸µ ±â±â : Á¦Ç°º° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Á¦Ç°º° ºÎ¹® ´ë½Ãº¸µå
- Á¦Ç°º° ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå Àü¸Á
- ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ±Ô¸ð ¹× µ¿Ç⠺м® : Á¦Ç°º°(2018-2030³â)
- ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â
- CÇ÷´ç ¸ð´ÏÅ͸µ ±â±â
Á¦5Àå Ç÷´ç ¸ð´ÏÅ͸µ ±â±â : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ºÎ¹® ´ë½Ãº¸µå
- ÃÖÁ¾ ¿ëµµº° ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå Àü¸Á
- ¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ±Ô¸ð ¹× µ¿Ç⠺м® : ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
- º´¿ø
- ÀçÅà Äɾî
- Áø´Ü¼¾ÅÍ
Á¦6Àå Áö¿ªº° ºñÁî´Ï½º ºÐ¼®
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- ¼¼°èÀÇ Áö¿ªº° ½ÃÀå ÇöȲ
- ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- Çѱ¹
- ű¹
- È£ÁÖ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦7Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷º° ÃÖ±ÙÀÇ µ¿Çâ ¹× ¿µÇ⠺м®
- ȸ»ç ¹× °æÀïÀÇ ºÐ·ù
- º¥´õ »óȲ
- Abbott
- Medtronic plc
- F. Hoffmann-La Roche Ltd
- Ascensia Diabetes Care Holdings AG
- LifeScan IP Holdings, LLC
- Dexcom, Inc
- SANOFI
- Lilly(Elly Lilly and Company)
- B Braun SE
AJY 24.03.21
Blood Glucose Monitoring Devices Market Growth & Trends:
The global blood glucose monitoring devices market size is expected to reach USD 23.21 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.25% from 2024 to 2030. Patients with diabetes and their healthcare professionals benefit significantly from Blood Glucose Monitoring Devices (BGMD). BGMD is becoming more widely accepted as an important component of intensive diabetic treatment. It allows diabetic patients to measure their blood sugar levels within minutes with ease and convenience wherever they are. The continuous glucose monitoring (CGM) devices help analyze the blood glucose level continuously and in real-time. It also helps patients determine the level of dietary intake and dosage of insulin. In addition, factors such as sedentary lifestyles including consumption of junk food, alcohol, and smoking, and a surge in the need for safer and faster diagnoses are expected to boost the market growth during the forecast period.
According to the International Diabetes Federation (IDF), the total number of diabetic patients is expected to expand to 643 million (11.3 %) by 2030 and 783 million (12.2 %) by 2045. Obesity is one of the major factors propelling the prevalence of diabetes. Obese individuals are up to 80 times more likely than non-obese persons to develop diabetes. Studies suggest that 650 million people over the age of 18 are obese. Further, due to the ongoing efforts by the government and healthcare organizations such as the International Diabetes Federation (IDF) to control diabetes, the market is likely to rise at a rapid pace throughout the forecast period. Through a network of stakeholders and collaborators, these organizations provide needed expertise and support diabetes awareness campaigns. Rising health-care funding is also expected to boost market growth.
Blood Glucose Monitoring Devices Market Report Highlights:
- North America held the largest revenue share in 2023 owing to favorable reimbursement policies, local presence of key players, and supportive government initiatives
- Based on product, the self-monitoring devices segment held the largest revenue share of 66.37% in 2023 and is expected to grow at a significant pace over the forecast period
- The continuous blood glucose monitoring devices product segment is expected to be the fastest-growing segment during the forecast period
- In the self-monitoring devices, the testing strips segment accounted for the largest revenue share in 2023 owing to the high usage of these strips and affordability.
- By end-use, the home care segment is expected to grow at a rapid pace during the forecast period
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Product Segment
- 1.1.1.2. End Use Segment
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Primary Sources
- 1.11. List of Abbreviations
Chapter 2. Blood Glucose Monitoring Devices Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Products and End Use Snapshots
- 2.3. Competitive Landscape Snapshot
Chapter 3. Blood Glucose Monitoring Devices Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Rising geriatric population worldwide
- 3.4.2. Increasing number of diabetes patients
- 3.4.3. Increasing awareness about diabetes preventive care
- 3.5. Market Restraint Analysis
- 3.5.1. High cost of devices
- 3.6. Blood Glucose Monitoring Devices Market Analysis Tools
- 3.6.1. Industry Analysis - Porter's
- 3.6.1.1. Supplier Power
- 3.6.1.2. Buyer Power
- 3.6.1.3. Substitution Threat
- 3.6.1.4. Threat Of New Entrant
- 3.6.1.5. Competitive Rivalry
- 3.6.2. PESTLE Analysis
- 3.6.2.1. Political Landscape
- 3.6.2.2. Technological Landscape
- 3.6.2.3. Economic Landscape
- 3.6.3. Pricing Analysis
Chapter 4. Blood Glucose Monitoring Devices: Product Estimates & Trend Analysis
- 4.1. Global Blood Glucose Monitoring Market: Product Segment Dashboard
- 4.2. Global Blood Glucose Monitoring Devices Market by Product Outlook
- 4.3. Global Blood Glucose Monitoring Devices Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Self-Monitoring Devices
- 4.4.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2. Blood Glucose Meter
- 4.4.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.3. Testing Strips
- 4.4.3.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.4. Lancets
- 4.4.4.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.5. Continuous Blood Glucose Monitoring Devices
- 4.5.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.5.2. Sensors
- 4.5.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.5.3. Transmitter & Receiver
- 4.5.3.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.5.4. Insulin Pumps
- 4.5.4.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
Chapter 5. Blood Glucose Monitoring Devices: End-use Estimates & Trend Analysis
- 5.1. Global Blood Glucose Monitoring Market: End-use Segment Dashboard
- 5.2. Global Blood Glucose Monitoring Market: End-use Movement Analysis
- 5.3. Global Blood Glucose Monitoring Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 5.4. Hospitals
- 5.4.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.5. Homecare
- 5.5.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6. Diagnostics Centers
- 5.6.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
Chapter 6. Regional Business Analysis
- 6.1. Regional Market Dashboard
- 6.2. Global Regional Market Snapshot
- 6.3. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
- 6.4. North America
- 6.4.1. U.S.
- 6.4.1.1. Key Country Dynamics
- 6.4.1.2. Competitive Scenario
- 6.4.1.3. Regulatory Framework
- 6.4.1.4. U.S. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.4.2. Canada
- 6.4.2.1. Key Country Dynamics
- 6.4.2.2. Competitive Scenario
- 6.4.2.3. Regulatory Framework
- 6.4.2.4. Canada Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5. Europe
- 6.5.1. UK
- 6.5.1.1. Key Country Dynamics
- 6.5.1.2. Competitive Scenario
- 6.5.1.3. Regulatory Framework
- 6.5.1.4. UK Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5.2. Germany
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Competitive Scenario
- 6.5.2.3. Regulatory Framework
- 6.5.2.4. Germany Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5.3. Spain
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Competitive Scenario
- 6.5.3.3. Regulatory Framework
- 6.5.3.4. Spain Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5.4. France
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Competitive Scenario
- 6.5.4.3. Regulatory Framework
- 6.5.4.4. France Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5.5. Italy
- 6.5.5.1. Key Country Dynamics
- 6.5.5.2. Competitive Scenario
- 6.5.5.3. Regulatory Framework
- 6.5.5.4. Italy Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5.6. Denmark
- 6.5.6.1. Key Country Dynamics
- 6.5.6.2. Competitive Scenario
- 6.5.6.3. Regulatory Framework
- 6.5.6.4. Denmark Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5.6.5.
- 6.5.7. Sweden
- 6.5.7.1. Key Country Dynamics
- 6.5.7.2. Competitive Scenario
- 6.5.7.3. Regulatory Framework
- 6.5.7.4. Sweden Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.5.8. Norway
- 6.5.8.1. Key Country Dynamics
- 6.5.8.2. Competitive Scenario
- 6.5.8.3. Regulatory Framework
- 6.5.8.4. Norway Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.6. Asia Pacific
- 6.6.1. Japan
- 6.6.1.1. Key Country Dynamics
- 6.6.1.2. Competitive Scenario
- 6.6.1.3. Regulatory Framework
- 6.6.1.4. Japan Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.6.2. China
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Competitive Scenario
- 6.6.2.3. Regulatory Framework
- 6.6.2.4. China Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.6.3. India
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Competitive Scenario
- 6.6.3.3. Regulatory Framework
- 6.6.3.4. India Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.6.4. South Korea
- 6.6.4.1. Key Country Dynamics
- 6.6.4.2. Competitive Scenario
- 6.6.4.3. Regulatory Framework
- 6.6.4.4. South Korea Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.6.5. Thailand
- 6.6.5.1. Key Country Dynamics
- 6.6.5.2. Competitive Scenario
- 6.6.5.3. Regulatory Framework
- 6.6.5.4. Thailand Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.6.6. Australia
- 6.6.6.1. Key Country Dynamics
- 6.6.6.2. Competitive Scenario
- 6.6.6.3. Regulatory Framework
- 6.6.6.4. Australia Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.7. Latin America
- 6.7.1. Brazil
- 6.7.1.1. Key Country Dynamics
- 6.7.1.2. Competitive Scenario
- 6.7.1.3. Regulatory Framework
- 6.7.1.4. Brazil Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.7.2. Mexico
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Competitive Scenario
- 6.7.2.3. Regulatory Framework
- 6.7.2.4. Mexico Blood Glucose Monitoring Devices Market, 2018 - 2030 (USD Million)
- 6.7.3. Argentina
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Competitive Scenario
- 6.7.3.3. Regulatory Framework
- 6.7.3.4. Argentina Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.8. MEA
- 6.8.1. South Africa
- 6.8.1.1. Key Country Dynamics
- 6.8.1.2. Competitive Scenario
- 6.8.1.3. Regulatory Framework
- 6.8.1.4. South Africa Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.8.2. Saudi Arabia
- 6.8.2.1. Key Country Dynamics
- 6.8.2.2. Competitive Scenario
- 6.8.2.3. Regulatory Framework
- 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.8.3. UAE
- 6.8.3.1. Key Country Dynamics
- 6.8.3.2. Competitive Scenario
- 6.8.3.3. Regulatory Framework
- 6.8.3.4. UAE Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 6.8.4. Kuwait
- 6.8.4.1. Key Country Dynamics
- 6.8.4.2. Competitive Scenario
- 6.8.4.3. Regulatory Framework
- 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 To 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company /Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List Of Key Distributors and Channel Partners
- 7.3.2. Key Customers
- 7.3.3. Key Company Market Share Analysis, 2023
- 7.3.4. Abbott
- 7.3.4.1. Overview
- 7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.4.3. Product Benchmarking
- 7.3.4.4. Strategic Initiatives
- 7.3.5. Medtronic plc
- 7.3.5.1. Overview
- 7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.5.3. Product Benchmarking
- 7.3.5.4. Strategic Initiatives
- 7.3.6. F. Hoffmann-La Roche Ltd
- 7.3.6.1. Overview
- 7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.6.3. Product Benchmarking
- 7.3.6.4. Strategic Initiatives
- 7.3.7. Ascensia Diabetes Care Holdings AG
- 7.3.7.1. Overview
- 7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.7.3. Product Benchmarking
- 7.3.7.4. Strategic Initiatives
- 7.3.8. LifeScan IP Holdings, LLC
- 7.3.8.1. Overview
- 7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.8.3. Product Benchmarking
- 7.3.8.4. Strategic Initiatives
- 7.3.9. Dexcom, Inc
- 7.3.9.1. Overview
- 7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.9.3. Product Benchmarking
- 7.3.9.4. Strategic Initiatives
- 7.3.10. SANOFI
- 7.3.10.1. Overview
- 7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.10.3. Product Benchmarking
- 7.3.10.4. Strategic Initiatives
- 7.3.11. Lilly (Elly Lilly and Company)
- 7.3.11.1. Overview
- 7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.11.3. Product Benchmarking
- 7.3.11.4. Strategic Initiatives
- 7.3.12. B Braun SE
- 7.3.12.1. Overview
- 7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.12.3. Product Benchmarking
- 7.3.12.4. Strategic Initiatives